148 related articles for article (PubMed ID: 7578657)
1. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.
Goodman WK; McDougle CJ; Price LH; Barr LC; Hills OF; Caplik JF; Charney DS; Heninger GR
Biol Psychiatry; 1995 Aug; 38(3):138-49. PubMed ID: 7578657
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo.
de Leeuw AS; Westenberg HG
J Psychiatr Res; 2008 Sep; 42(11):894-901. PubMed ID: 18533183
[TBL] [Abstract][Full Text] [Related]
3. Behavioral and neuroendocrine responses to metaCPP in anorexia nervosa.
Hadigan CM; Walsh BT; Buttinger C; Hollander E
Biol Psychiatry; 1995 Apr; 37(8):504-11. PubMed ID: 7619973
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile.
Feuchtl A; Bagli M; Stephan R; Frahnert C; Kölsch H; Kühn KU; Rao ML
Pharmacopsychiatry; 2004 Jul; 37(4):180-8. PubMed ID: 15467976
[TBL] [Abstract][Full Text] [Related]
5. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
Gross-Isseroff R; Cohen R; Sasson Y; Voet H; Zohar J
Neuropsychobiology; 2004; 50(3):200-5. PubMed ID: 15365215
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
Khanna S; John JP; Reddy LP
Psychoneuroendocrinology; 2001 Feb; 26(2):209-23. PubMed ID: 11087965
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.
Pigott TA; Hill JL; Grady TA; L'Heureux F; Bernstein S; Rubenstein CS; Murphy DL
Biol Psychiatry; 1993 Jan; 33(1):3-14. PubMed ID: 8420593
[TBL] [Abstract][Full Text] [Related]
8. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.
Hollander E; DeCaria C; Gully R; Nitescu A; Suckow RF; Gorman JM; Klein DF; Liebowitz MR
Psychiatry Res; 1991 Jan; 36(1):1-17. PubMed ID: 2017519
[TBL] [Abstract][Full Text] [Related]
9. Low versus standard dose mCPP challenge in obsessive-compulsive patients.
Erzegovesi S; Martucci L; Henin M; Bellodi L
Neuropsychopharmacology; 2001 Jan; 24(1):31-6. PubMed ID: 11106873
[TBL] [Abstract][Full Text] [Related]
10. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL
Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder.
McDougle CJ; Goodman WK; Leckman JF; Barr LC; Heninger GR; Price LH
J Clin Psychopharmacol; 1993 Oct; 13(5):354-8. PubMed ID: 8227493
[TBL] [Abstract][Full Text] [Related]
12. [Validation of a scale for responsibility (Salkovskis Responsibility Scale)].
Bouvard M; Robbe-Grillet P; Milliery M; Pham S; Amireche S; Fanget F; Guerin J; Cottraux J
Encephale; 2001; 27(3):229-37. PubMed ID: 11488253
[TBL] [Abstract][Full Text] [Related]
13. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor.
Stein DJ; Van Heerden B; Wessels CJ; Van Kradenburg J; Warwick J; Wasserman HJ
Prog Neuropsychopharmacol Biol Psychiatry; 1999 Aug; 23(6):1079-99. PubMed ID: 10621951
[TBL] [Abstract][Full Text] [Related]
14. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR
Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615
[TBL] [Abstract][Full Text] [Related]
15. Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder.
Katzman MA; Koszycki D; Bradwejn J
Depress Anxiety; 2004; 20(2):51-8. PubMed ID: 15390214
[TBL] [Abstract][Full Text] [Related]
16. Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology.
Korff S; Harvey BH
Psychiatr Clin North Am; 2006 Jun; 29(2):371-90. PubMed ID: 16650714
[TBL] [Abstract][Full Text] [Related]
17. Empathy and symptoms dimensions of patients with obsessive-compulsive disorder.
Fontenelle LF; Soares ID; Miele F; Borges MC; Prazeres AM; Rangé BP; Moll J
J Psychiatr Res; 2009 Jan; 43(4):455-63. PubMed ID: 18614180
[TBL] [Abstract][Full Text] [Related]
18. Neurobiology of obsessive compulsive disorder: a possible role for serotonin.
Winslow JT; Insel TR
J Clin Psychiatry; 1990 Aug; 51 Suppl():27-31; discussion 55-8. PubMed ID: 2199432
[TBL] [Abstract][Full Text] [Related]
19. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
Zohar J; Mueller EA; Insel TR; Zohar-Kadouch RC; Murphy DL
Arch Gen Psychiatry; 1987 Nov; 44(11):946-51. PubMed ID: 3675134
[TBL] [Abstract][Full Text] [Related]
20. The distinctiveness of compulsive hoarding from obsessive-compulsive disorder.
Grisham JR; Brown TA; Liverant GI; Campbell-Sills L
J Anxiety Disord; 2005; 19(7):767-79. PubMed ID: 16076423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
